2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

2:30PM-4:00PM: Abstract Number: 854

First and Recurrent Thrombosis Risk after 1897 Patient-Years of Follow-up: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)

3S079 ACR Abstract: Antiphospholipid Syndrome (851–856)

2:30PM-4:00PM: Abstract Number: 873

General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout

3S083 ACR Abstract: Metabolic & Crystal Arthropathies: Comorbidities & Outcomes (869–874)

2:30PM-4:00PM: Abstract Number: 885

Herpes Zoster in Tofacitinib Users with and without Concomitant Methotrexate and Glucocorticoids

3S086 ACR Abstract: RA–DX, Manifestations, & Outcomes I: Other Co-Morbidities (880–885)

2:30PM-4:00PM: Abstract Number: 893

Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods

3S088 ACR Abstract: Spondyloarthritis Incl PsA–Clinical I: Axial SpA Epidemiology (892–897)

2:30PM-4:00PM: Abstract Number: 878

IFN Level Assessed By Ultrasensitive Detection Technology in Myositis Patient: A Promising Biomarker of Disease Activity in Dermatomyositis and Anti-Synthetase Syndrome

3S084 ACR Abstract: Muscle Biology, Myositis & Myopathies I: Biomarkers (875–879)

2:30PM-4:00PM: Abstract Number: 855

IgG Antiphospholipid Antibodies, -a Common but Neglected Finding in Patients with Myocardial Infarction

3S079 ACR Abstract: Antiphospholipid Syndrome (851–856)

2:30PM-4:00PM: Abstract Number: 879

IL-31 Protein Expression in Lesional Skin Correlates with Itch in Dermatomyositis

3S084 ACR Abstract: Muscle Biology, Myositis & Myopathies I: Biomarkers (875–879)

2:30PM-4:00PM: Abstract Number: 910

In Diagnostic Prevalence and Treatment Patterns of Male and Female Ankylosing Spondylitis Patients in the United States, 2006-2016

3S093 ACR/ARHP Abstract: Epidemiology & Pub Health (910–915)

2:30PM-4:00PM: Abstract Number: 914

Increased Adverse Childhood Experiences in Children with Arthritis: An Analysis of the National Survey of Children’s Health

3S093 ACR/ARHP Abstract: Epidemiology & Pub Health (910–915)

2:30PM-4:00PM: Abstract Number: 856

Integrated mRNA and microRNA Transcriptomes of Monocytes from Antiphospholipid Syndrome Patients Identifies Molecular Networks Related to Their Atherothrombotic Status. Modulatory Effects of In Vivo Ubiquinol Supplementation

3S079 ACR Abstract: Antiphospholipid Syndrome (851–856)

2:30PM-4:00PM: Abstract Number: 851

Integrin Mac-1 Potentiates Neutrophil Adhesion and NET Release in Antiphospholipid Syndrome

3S079 ACR Abstract: Antiphospholipid Syndrome (851–856)

2:30PM-4:00PM: Abstract Number: 842

Interleukin 17 Receptor D (IL-17RD) Is Regulated By Pro-Inflammatory Cytokines and Plays a Role in the Development of Collagen-Induced Arthritis

3S080 ACR Abstract: Cytokines & Cell Trafficking (840–845)

2:30PM-4:00PM: Abstract Number: 868

International Multi-Reader Validation of the Outcome Measures in Rheumatology Hip MRI Scoring System (OMERACT HIMRISS) for Bone Marrow Lesions in Osteoarthritis

3S082 ACR Abstract: Imaging of Rheumatic Diseases I: MRI & CT (863–868)

2:30PM-4:00PM: Abstract Number: 872

Is the Serum Uric Acid Therapeutic Target Protective of Chronic Kidney Disease, Cardiovascular Disease, and Mortality for Patients with Gout? a Longitudinal Study

3S083 ACR Abstract: Metabolic & Crystal Arthropathies: Comorbidities & Outcomes (869–874)

2:30PM-4:00PM: Abstract Number: 843

Localization of the Voltage-Gated Sodium Channel 1.7 in Peripheral Monocytes Contributes to Activation of BAFF Signaling in Monocytes of Patients with Primary Sjögren’s Syndrome

3S080 ACR Abstract: Cytokines & Cell Trafficking (840–845)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].